Anatara Lifesciences Ltd

ASX:ANR ISIN:AU000000ANR0

Anatara Lifesciences ASX ANRAnatara Lifesciences (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anatara is a life sciences company with expertise in developing products for animal and human health. Anatara is focused on building a pipeline of human gastrointestinal health products. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders. For more information, please visit www.anataralifesciences.com.

     

News

Anatara Lifesciences Ltd (ASX:ANR) PAC Partners Equity Research Report

🕔7/15/2019 11:43:23 AM 798

PAC Partners Equity Research has released its latest research and valuation report on Anatara Lifesciences (ASX:ANR). The report provided a SPEC BUY rating and a 12-month price target of $0.90 per share.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Animal Health Asset Update

🕔6/28/2019 9:49:25 AM 1473

Anatara Lifesciences (ASX:ANR) provides an update on the strategic evaluation of Detach(R), its non-antibiotic animal health asset which aids in the control of diarrhoeal disease in piglets with potential application in other livestock animals, aquaculture and companion animals.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Investor Presentation

🕔6/17/2019 8:32:41 AM 1715

Anatara Lifesciences (ASX:ANR) releases the presentation which Chief Executive Officer, Mr Steven Lydeamore, will present to investors in Perth this week and to the Gold Coast Investment Showcase later this month.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Retains Global Market for Detach

🕔6/14/2019 9:24:02 AM 1986

Anatara Lifesciences (ASX:ANR) announces that Zoetis Inc. has given notice of termination of the exclusive worldwide license of Detach(R) for livestock and horses. Zoetis made a portfolio decision not to continue with the pursuit of this asset.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Shareholder Information Session - Perth

🕔6/4/2019 11:26:17 AM 2214

Anatara Lifesciences Ltd (ASX:ANR) is pleased to invite existing and potential shareholders to attend an information briefing session in Perth to discuss the Company's work in gastrointestinal health and to meet Chief Executive Officer, Steven Lydeamore.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) PAC Partners Equity Research Report

🕔5/17/2019 10:26:26 AM 2380

In the lead up to World IBD Day, this coming Sunday, 19th May, PAC Partners Equity Research has released its latest research and valuation report on Anatara Lifesciences (ASX:ANR). The report provided a BUY rating and a 12-month price target of $1.40 per share.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Unite for World IBD Day and Crohn's and Colitis Awareness Month

🕔5/14/2019 10:40:51 AM 2277

The month of May marks two very important days in the IBD calendar - Crohn's and Colitis Awareness Month, which takes place throughout May and World IBD Day, which is being held this Sunday, 19 May. Both events are designed to raise awareness for Crohn's disease and Ulcerative colitis, and show support to the 10 million people worldwide who live with IBD.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Finance News Network Interviews CEO Steven Lydeamore

🕔5/2/2019 4:54:08 PM 2273

While in Sydney last month, Anatara Lifesciences (ASX:ANR) CEO Steve Lydeamore sat down with Anna Napoli at Finance News Network, Australia's largest provider of online business and finance news.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Quarterly Report

🕔4/30/2019 8:50:52 AM 1619

Anatara Lifesciences Ltd (ASX:ANR) is pleased to release its Appendix 4C for the quarter ending 31st March 2019. The Company's cash plus term deposits at the end of the quarter stood at $6.4m, incorporating receipt of the 2017-2018 $1.249m R&D tax refund which was received on 14th January 2019. On 31st March 2019, the Company had cash at bank of $1,395,664 and $5,050,000 in term deposits.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Pitt Street Research Interviews CEO Steven Lydeamore

🕔4/16/2019 10:53:59 AM 2280

While in Sydney earlier this month, Anatara Lifesciences (ASX:ANR) CEO Steve Lydeamore sat down with Stuart Roberts at Pitt Street Research, one of Australia's most experienced providers of equity research for ASX-listed small and mid cap companies.

Read Full Article
###

0 COMPANY PROFILE VIEWS

  • This Page Viewed: (Last 7 Days: 318) (Last 30 Days: 1292) (Since Published: 37374) 

Markets ASX:ANR

Company Data

    Headquarters
  • 433 Logan Road, Stones Corner
    Brisbane, Queensland 4120
    Australia
  • Principal Sector
  • Biotech 
  • Principal Industry
  • Biotechnology 
  • Homepage
  • www.anataralifesciences.com
  • E:
  • info@anataralifesciences.com

Company Reports

Presentations

Research Report

Quarterly Report

Social Media